These are stressful times. If you would like to contact a social worker, psychologist or child life specialist for information on community referrals or coping resources, you can call 312.227.4118 and leave a message. Your call will be returned within 24 hours, Monday through Friday. Non-urgent questions only. For emergencies, call 911.
For information about telemedicine appointments, click here.
For information on Novel Coronavirus (COVID-19), click here.
Para obtener información sobre el COVID-19 en español, haga clic aquí.
The checklist below is for evaluating whether a clinical trial or study is an Applicable Clinical Trial (ACT) under 42CRF 11.22(b) for the clinical trials initiated on or after January 18, 2017.
1. Is the study interventional (a clinical trial)?
2. Do ANY of the following apply?
Is at least one study facility located in the United States or a U.S. territory?
Is the study conducted under a U.S. FDA Investigational New Drug application (IND) or Investigational Devise Exemption (IDE)?
Does the study involve a drug, biological or device product manufactured in and exported from the U.S. or a U.S. territory for study in another country?
3. Does the study evaluate at least one drug, biological, or device product regulated by the U.S. FDA?
4. Is the study other than a Phase 1 trial of a drug and/or biological product or is the study other than a device feasibility study?
If you answer YES to all 4 questions and the study was initiated on or after January 18, 2017, the trial would meet the definition of an ACT that is required to be registered on Clinical Trials.gov under 42 CFR 11.2